Blueprint Medicines Corp logo

Blueprint Medicines Corp

$ 66.42 +0.53 (+0.8%) 10:08 PM EST
P/E:
At Loss
P/B:
5.29
Market Cap:
$ 3.97B
Enterprise V:
$ 3.19B
Volume:
308.60K
Avg Vol (2M):
893.42K
Also Trade In:
Volume:
308.60K
Market Cap $:
3.97B
PE Ratio:
At Loss
Avg Vol (2-Month):
893.42K
Enterprise Value $:
3.19B
PB Ratio:
5.29
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Name Current Vs Industry Vs History
Cash-To-Debt 7.93
Equity-to-Asset 0.63
Debt-to-Equity 0.14
Debt-to-EBITDA -0.16
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.57
Distress
Grey
Safe
Beneish M-Score -3.98
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 45.25
9-Day RSI 43.35
14-Day RSI 45.7
6-1 Month Momentum % 11.5
12-1 Month Momentum % -28.31

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6
Quick Ratio 5.77
Cash Ratio 5.37
Days Inventory 408.44
Days Sales Outstanding 39.56
Days Payable 180.73

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.3

Financials (Next Earnings Date:2022-10-28 Est.)

BPMC's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BPMC

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 230.487
EPS (TTM) ($) -11.87
Beta 0.4
Volatility % 64.45
14-Day RSI 45.7
14-Day ATR ($) 3.416231
20-Day SMA ($) 69.875
12-1 Month Momentum % -28.31
52-Week Range ($) 43.46 - 117.86
Shares Outstanding (Mil) 59.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Blueprint Medicines Corp Filings

Document Form Filing Date
No Filing Data

Blueprint Medicines Corp Analysis

Share your research

Headlines

See More
No news.